The #1 podcast in medtech and medical devices.
Hosted by Omar M. Khateeb, State of Medtech explores the business and science behind the world’s most disruptive healthcare technologies.
Each week, you’ll hear from:
Leading venture capitalists & investors
Founders and CEOs of high-growth medtech startups
Industry executives and clinicians shaping the future of medicine
Whether you’re building, investing in, or adopting medical technology, this show gives you the insider playbook—from GTM strategy and regulatory insights to funding, clinical adoption, and M&A.
🎯 Learn what it takes to scale a medtech company
📈 Discover what investors are really looking for
🔍 Stay ahead of the trends transforming healthcare
New episodes weekly. Ranked #1 for a reason.
Advertise on State of Medtech
Advertise on State of Medtech to promote your brand to thousands of podcast listeners
Unlock State of Medtech podcast Email contact info, Listeners & Audience details
Email contact information
Direct podcast contact details
Listeners
Audience numbers & engagement insights
Audience details
Podcast Insights
Podcast episodes
Check latest episodes from State of Medtech podcast
Endoscopic Metabolic Restoration: Aqua Medical’s New Approach to Type 2 Diabetes with Bob Haggerty
2026/11/08
Could the gastrointestinal tract become an important new therapeutic target for Type 2 diabetes?
In this episode, Omar Khateeb sits down with Bob Haggerty, President and CEO of Aqua Medical, to explore how advances in therapeutic endoscopy could expand the way metabolic disease is treated.
Aqua Medical is developing an investigational procedure called PIMA as part of a broader category known as Endoscopic Metabolic Restoration. Using a standard endoscope, the technology delivers controlled radiofrequency-generated water vapor to the proximal intestinal mucosa, with the goal of influencing the metabolic signaling involved in glycemic control.
Bob discusses early clinical experience from 66 patients treated internationally, where Aqua Medical observed average A1C reductions in the approximately 2.1 to 2.6-point range at one year. He explains why the small intestine has become an area of interest in metabolic medicine and how treating dysfunctional mucosa may potentially complement existing diabetes therapies.
The discussion also examines the role of GLP-1 medications, insulin, oral therapies, lifestyle changes, and how a future procedural option could fit within that broader continuum of care.
From a MedTech strategy perspective, Bob explains why Aqua Medical designed the procedure around existing GI workflow, standard endoscopes, outpatient surgery centers, and technology familiar to practicing gastroenterologists.
Omar and Bob also discuss the company’s Series B financing, U.S. clinical development, planned pivotal study, healthcare economics, product iteration, and what must happen before an investigational technology can move toward broader commercialization.
For healthcare executives, clinicians, founders, and investors, the episode provides a practical look at the intersection of gastroenterology, metabolic disease, medical devices, and category creation.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
#type2diabetes #diabetestreatment #medtechinnovation #medicaldevices #metabolichealth
Intuitive Ventures Playbook: $5M to $10M Bets, Clinical Evidence and Market Creation with Terri Burke
2026/11/03
MedTech founders spend years proving that a technology can work. Investors are asking a bigger question: can it become a business capable of changing care and creating lasting value?
In this episode, Omar Khateeb sits down with Terri Burke, Senior Partner at Intuitive Ventures, for a wide-ranging discussion on healthcare venture capital, MedTech commercialization, AI, category creation, and what separates promising technologies from investable companies.
Terri’s career spans more than three decades across operating, founding, and investing, giving her a perspective shaped by both building companies and deciding where capital should go. She explains how Intuitive Ventures approaches next-horizon healthcare opportunities that extend far beyond surgical robotics, with an emphasis on major unmet clinical needs, less invasive treatment, stronger economics, and platforms capable of transforming care.
They explore why the venture market has shifted toward greater de-risking, what Intuitive Ventures looks for around first-in-human development, and why an initial $5 million to $10 million investment requires more than a compelling technology.
Terri also shares her perspective on AI and healthtech, including opportunities in cardiology, imaging, earlier diagnosis, and clinical decision support. Her framework keeps the physician and clinical evidence at the center while pressure-testing the business model behind the technology.
The conversation ultimately comes back to a critical distinction for founders: a valuable product is not automatically a venture-backable business. Companies need to understand who will use the technology, why they need it, who will pay for it, how frequently it will be used, what milestones must be proven, and where strategic value could emerge over time.
Omar and Terri also discuss early-stage traction, category-defining innovation, building investor relationships, communicating milestones, establishing a brand before commercialization, and why successful founders need to understand the market as deeply as they understand the technology.
DISCLAIMER:
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
#medtechrevolution #venturecapital #medtechinnovation #healthcarestartup #medtechindustry
Cardio: How AI Is Fighting Heart Attacks: Coronary Inflammation, Plaque & Heart Attack Prevention | Steve Deitsch
2026/11/01
Cardiovascular AI is beginning to move beyond identifying anatomy toward revealing biological risk that clinicians could not previously quantify from routine imaging.
In this episode, Omar Khateeb sits down with Steve Deitsch, CEO of Caristo Diagnostics, to examine how coronary inflammation could reshape preventive cardiology and what it takes to transform an FDA-authorized technology into a scalable MedTech business.
Caristo’s CaRi-Heart platform uses AI to analyze coronary CT angiography and assess inflammation associated with future cardiovascular risk. Steve explains why this information could complement existing approaches such as calcium scoring, plaque analysis, and FFR-CT by providing another dimension of risk before severe obstruction becomes the defining signal.
The conversation also examines the commercial challenge ahead. Steve discusses US team building, reimbursement, adoption, clinical evidence, and the opportunity to build on an existing CCTA workflow rather than requiring an entirely new hardware infrastructure.
A 2,000-patient NHS pilot becomes an important example, with Steve citing nearly 60% of patients receiving a change in clinical management after inflammation analysis was introduced. He also outlines future opportunities in asymptomatic screening, heart failure, AFib, stroke prediction, and the use of coronary inflammation measurements in pharmaceutical development.
Steve then draws on his experience helping lead OrganOx through its $1.5 billion sale to Terumo, explaining why enterprise value comes from solving significant unmet needs, directing capital toward the right initiatives, executing consistently, and building a company with multiple strategic paths.
The result is a conversation about more than cardiac AI. It is a deeper look at category creation, commercialization, preventive care, and how MedTech companies build enduring strategic value.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any security. Conduct your own due diligence.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
#medtechinnovation #cardiovascularhealth #aiinhealthcare #heartdiseaseprevention #medtechrevolution
This Month in MedTech: Stryker’s $400M Robotics Bet on CMR, J&J’s $400M Reset and the New Strategic Playbook with Henry Peck, CBO at LSI
2026/10/27
In this episode, Omar Khateeb sits down with Henry Peck, Chief Business Officer at LSI, to examine the market signals emerging from more than $4 billion in European MedTech exits and a wave of strategic activity across surgical robotics, cardiovascular devices, diagnostics, neuromodulation, and commercialization.
One of the most revealing data points comes directly from LSI’s market intelligence. Among more recent LSI Europe companies, 77% are pursuing an FDA-first strategy, while roughly 14% identify CE Mark or MDR as their first pathway, reflecting a meaningful change in how European innovators are approaching global commercialization.
Omar and Henry explore why strategic partnerships are also moving earlier in the company-building process. Capital remains important, but founders increasingly need partners that can validate demand, expand distribution, reduce commercialization risk, and connect promising technology with an established market.
The episode examines J&J’s approximately $400 million Laminar acquisition, the subsequent decision to move the asset outside J&J, and a broader lesson about disciplined portfolio management when clinical development, market dynamics, and strategic priorities evolve.
They also go deep into surgical robotics, where a roughly $180 million acquisition, Stryker’s approximately 3,000 installed Mako systems, and a $400 million investment in CMR Surgical reveal how much strategic value can come from installed base, recurring implant revenue, regulatory know-how, and ecosystem control.
Beyond the headline transactions, Henry highlights promising companies across epilepsy neuromodulation, brain PET imaging, cardiovascular technology, dialysis access, and orthopedics while explaining what separates compelling science from a commercially scalable MedTech business.
The episode offers a data-driven look at how MedTech capital, M&A, regulatory strategy, and commercialization are evolving as the industry moves toward 2027.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#medtech #medtechinnovation #surgicalrobotics #medtechinnovation #medicaldeviceindustry
TechMed: Building Category-Defining Healthcare Companies at Software Speed with Nick Damiano of Andromeda Surgical and Dave Messina of Pioneer Fund
2026/10/25
The future of MedTech may depend as much on how companies are built as on the technologies they invent.
In this episode, Omar Khateeb sits down with Nick Damiano, Co-founder and CEO of Andromeda Surgical, and Dave Messina, General Partner at Pioneer Fund, to explore how TechMed, autonomous surgery, software-driven iteration, and founder-led leadership could reshape healthcare innovation.
Nick shares Andromeda Surgical’s approach to building autonomy through a focused clinical beachhead rather than attempting a general robotic surgeon immediately. The company uses rapid feedback cycles with surgeons, stepwise regulatory progress, internal automation, and accumulated procedural data to improve the platform and expand toward additional use cases.
Dave explains why early-stage investing requires a different lens when revenue is not yet the most meaningful signal. Pioneer Fund looks for founders who move quickly, think differently about established industries, understand large problems deeply, and demonstrate enough momentum to compound learning over time.
Omar, Nick, and Dave also examine why utilization and data can sometimes create more long-term platform value than maximizing initial revenue, why founder energy matters during difficult periods, and why AI does not eliminate the need for strong customers, commercialization, execution, and business fundamentals.
The conversation offers a broader thesis for MedTech: build narrowly enough to learn quickly, but design the company and platform for a much larger future.
DISCLAIMER:
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Conduct your own due diligence and consult qualified professionals.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE:
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Medtech CEO Camp: https://www.campcuriae.com/
#autonomousrobots #surgicalrobotics #medtechinnovation #physicalai #medtechindustry
a16z State of Markets 2026: Why MedTech Could Be the Next Big Investment Opportunity
2026/10/22
The shift from software to physical AI could change how investors evaluate MedTech.
In this episode, Omar Khateeb breaks down a16z’s State of Markets 2026 report and asks whether the return of capital-intensive technology could open a new investment window for healthcare innovation.
For years, MedTech founders have competed against software companies with faster development cycles, lower marginal costs, and earlier revenue. Medical devices require manufacturing, regulatory approval, clinical evidence, physician adoption, and expensive commercialization infrastructure.
a16z’s broader market analysis suggests investors are becoming increasingly interested in technologies that require physical infrastructure again, including robotics, semiconductors, energy, defense, and AI infrastructure.
Omar explores why that matters for surgical robotics, physical AI, AI-enabled diagnostics, automation, and intelligent medical devices.
The episode also looks at a major shift in fundraising strategy. MedTech founders cannot rely on clinical differentiation alone. They need to demonstrate venture-scale economics, category leadership, defensibility, commercialization potential, and a compelling reason their technology can capture a meaningful market.
Omar also explains why healthcare may have an advantage as AI enters its “prove it” era. MedTech companies already operate in a world where claims require evidence, clinical outcomes matter, and customers expect measurable value before adoption.
The opportunity is not simply more AI inside medical devices. It is building clinically meaningful physical technology that investors can understand as both breakthrough healthcare and a great business.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston: https://www.campcuriae.com/
#medtech #physicalai #venturecapital #surgicalrobotics #medtechindustry
Space Medicine: Designing Healthcare for Life Beyond Earth with Matthew Kuhn of Skybound Medtech
2026/10/18
The next great challenge in space exploration may not be transportation. It may be keeping the human body healthy enough to stay there.
In this episode, Omar Khateeb sits down with Matthew Kuhn, Founder and CEO of Skybound Medtech, to examine the intersection of space medicine, autonomous healthcare, medical robotics, human performance, and deep-tech commercialization.
Matthew shares the thinking behind Skybound and his provocative thesis that gravity itself may represent a constraint medicine has never had to seriously reconsider.
That question becomes increasingly important as spaceflight moves toward longer missions and larger populations. Microgravity can rapidly affect muscle and bone, while future missions to Mars introduce communication delays that make conventional telemedicine and real-time medical consultation increasingly difficult.
Omar and Matthew explore why those constraints may accelerate autonomous robotics, reusable medical technology, local decision-making systems, and new ways of interacting with human physiology.
The conversation also examines the commercial opportunity behind the science. Matthew describes Skybound as a venture studio working at the intersection of space, defense, and clinical medicine, with the goal of developing technologies that address mission-critical space health challenges while remaining relevant to terrestrial healthcare.
They also discuss venture capital, MedTech risk, moonshot innovation, physical AI, medical simulation, and the idea of using an ambitious long-term mission to generate multiple commercially valuable technologies along the way.
The deeper opportunity is to treat space not only as a destination, but as an innovation environment capable of forcing medicine to solve problems in entirely new ways.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#spacemedicine #medtechinnovation #spaceexploration #medicalrobotics #healthcareinnovation #medtech
Scalable Surgery: Predictability, Efficiency and the ASC Opportunity with Jeffery Alvarez of Moon Surgical
2026/10/13
The next generation of surgical robotics may be defined as much by economics and workflow as by clinical capability.
In this episode, I sit down with Jeffery Alvarez, Chief Strategy Officer at Moon Surgical, to explore how Scalable Surgery, physical AI, and ASC innovation could change the way surgical care is delivered.
Jeffery explains why the traditional approach of solving rising surgical demand by adding more operating rooms, surgeons, staff, and technology is becoming increasingly difficult. Instead, he argues that healthcare needs systems designed around predictability, efficiency, accessibility, and flexibility across different sites of care.
That thesis is central to Moon Surgical’s Maestro platform.
Jeffery describes Maestro as a physical AI platform with perception, local computing, intelligence, and physical action built into the system. We discuss its FDA-cleared Copilot functionality, automated visualization, intelligent setup, portability, and how these capabilities are designed to reduce variability around the surgical workflow.
We also examine the economics of ambulatory surgery centers, where high-volume facilities may complete significantly more procedures per room while turning cases much faster than traditional academic centers.
Jeffery shares Moon Surgical’s reported evidence showing lower staffing requirements, shorter average procedure times, and meaningfully greater predictability across hundreds of procedures.
The conversation also covers marginal cost of productivity, outpatient reimbursement, AI ecosystems, network effects, surgical workflow design, category creation, and the discipline required to build a startup around the needs of a specific market.
The deeper opportunity is not simply creating another surgical robot.
It is designing technology that allows more patients to receive high-quality surgical care with fewer resources and greater operational predictability.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#surgicalrobotics #scalablesurgery #physicalai #medtechinnovation #moonsurgical
Remote Surgery: Building the Infrastructure for Care Beyond Geography with Brian Miller of SOVATO
2026/10/11
The future of surgery may be defined less by where the surgeon is located and more by how reliably expertise can reach the patient.
In this episode, I sit down with Brian Miller, CEO of SOVATO, to explore the infrastructure, robotics, and AI required to make remote procedures a scalable model of healthcare delivery.
Brian explains why successful remote care requires much more than connecting a robotic system to a network. Hospitals also need reliable performance, secure connectivity, intelligent bandwidth management, clinical protocols, workforce planning, reimbursement pathways, and operational systems that allow remote care to function consistently.
We discuss how remote capabilities could change specialist coverage across large healthcare systems. Brian shares an example where a thirty-hospital network might eventually be supported by a much smaller centralized group of specialists rather than requiring individual coverage at every facility.
The conversation also explores the possibility of centralized surgeon cockpits, where physicians could connect into procedures across multiple hospitals while maintaining the situational awareness required for safe patient care.
Brian identifies robotic ultrasound, interventional radiology, urology, cancer surgery, stroke care, and mechanical thrombectomy as areas where remote capabilities could become particularly valuable.
We also go deeper into AI-enabled surgical autonomy, deterministic cloud computing, surgical video data, outcome prediction, CMS reimbursement discussions, healthcare workforce shortages, and the growing influence patients may have on access to specialized care.
Ultimately, remote care is about something larger than robotics. It is about building infrastructure that allows healthcare systems to project expertise across distance and give more patients access to the right care at the right time.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#remotesupport #surgicalrobotics #medtech #healthcareinnovation #medicalrobotics
Career: Omar M. Khateeb on building a career in medtech, the state of venture capital and more
2026/10/05
In this episode, Jacob McLaughlin sits down with Omar Khateeb to explore how medical device professionals can turn field experience into broader business judgment, leadership capability, and long-term career leverage.
Omar shares his journey from medical device sales and surgical robotics into marketing, Silicon Valley, entrepreneurship, and building MarketCraft around the concept of MedTech market engineering.
The conversation examines why medical device sales can become an unusually valuable business education. Reps work directly with physicians, hospitals, clinical workflows, logistics, budgets, technology adoption, and customer behavior, which can create a strong foundation for future roles in leadership, marketing, commercialization, and entrepreneurship.
Jacob and Omar discuss why professionals should invest in their own development before an organization formally asks them to lead. Learning management principles, understanding P&L decisions, attending industry conferences, studying deeply, building relationships, and taking ownership of complex work can all increase professional leverage.
The conversation also moves into category creation, positioning, messaging, thought leadership, fundraising, early clinical traction, and go-to-market strategy for MedTech startups.
Omar explains how beachhead markets and reference density can help companies establish credibility before expanding, while first-principles thinking can help leaders question requirements, simplify systems, automate intelligently, and scale more effectively.
The broader message is clear: the strongest careers and companies are often built by people willing to think several steps ahead of their current position.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#surgicalrobotics #medtech #surgery #medicalrobotics #healthcareinnovation
Surgical Innovation: From Cardiac Robotics to Remote Surgery with Sudhir Srivastava, MD of SS Innovations
2026/10/04
In this episode, Omar Khateeb speaks with Sudhir Srivastava, MD, Founder, Chairman & CEO of SS Innovations International Inc., about the evolution of surgical robotics and a future where surgical expertise can increasingly move across geography instead of requiring patients to travel toward it.
Dr. Srivastava shares how decades in cardiac surgery shaped his view of minimally invasive care and eventually led him to build SS Innovations around a patient-centered goal: expanding access to advanced robotic surgery while reducing the barriers created by cost and geography.
The conversation explores the development of the SSi Mantra platform and SS Innovations’ work in telesurgery. Dr. Srivastava says the company has completed nearly 200 telesurgeries , including robotic cardiac cases, and describes procedures performed across distances of 10,000 and 20,000 kilometers.
He also discusses performing cardiac surgery remotely from his home, completing 24 telesurgeries in 12 hours with a team of surgeons, and using telepresence to mentor clinicians thousands of kilometers away.
The discussion expands into the infrastructure surrounding next-generation surgery, including connectivity, AI, machine learning, semi-automation, remote ultrasound and biopsy, mobile operating rooms, surgeon education, and robotic technologies designed for emergency and underserved environments.
For surgeons, MedTech executives, investors, and healthcare leaders, the episode provides a deeper look at how surgical robotics could evolve from a sophisticated operating-room platform into a broader system for extending expertise, training clinicians, and democratizing access to advanced care.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#surgicalrobotics #medtech #surgery #medicalrobotics #healthcareinnovation
MedTech Venture Growth: Becoming Magnetic to Capital, Clinicians and Talent
2026/09/29
In this solo episode, Omar Khateeb introduces a market engineering framework for MedTech founders who want to create stronger investor demand, clinical adoption, strategic visibility, recruiting leverage, and internal alignment.
The thesis begins with a simple observation: companies frequently approach investors, physicians, strategics, and talented executives only when they need something from them. Omar argues that stronger companies begin building those relationships much earlier by consistently making their progress visible and understandable.
Using the physics of magnetism as an analogy, Omar explains how founder vision, clinical milestones, physician validation, employee advocacy, investor attention, PR, social media, and market positioning become more powerful when every signal points in the same direction.
This changes fundraising because investors can follow the company long before a financing round begins. They can watch the technology mature, see respected people join, observe clinical progress, and recognize physician engagement before receiving an investment deck.
The same principle can influence commercialization and clinical adoption. Early physician innovators can validate the technology publicly, while their participation becomes another credibility signal visible to investors, strategic partners, employees, and potential recruits.
Omar also explores why founders should begin recruiting before a position becomes available. Strong executives can follow a compelling company journey over time and eventually approach an opportunity with familiarity, context, and belief already established.
The episode ultimately reframes social media as an infrastructure for distributing evidence of progress. When that evidence compounds consistently over two or three years, MedTech companies can become increasingly magnetic to the capital, clinicians, talent, and strategic relationships required for growth.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#medtech #medtechinnovation #marketanalysis #medtechindustry #healthcareinnovation
Venture Capital: Jenny Barba and Jeff Chu of Features Capital
2026/09/28
In this episode, Omar Khateeb sits down with Jenny Barba and Jeff Chu, Co-Founders and Managing Partners at Features Capital, for a detailed discussion on early-stage MedTech venture capital, clinical adoption, commercialization, capital efficiency, and the signals investors look for before a company reaches first-in-human studies or meaningful revenue.
Jenny brings a finance and venture perspective shaped by billions of dollars in MedTech transactions, while Jeff brings decades of experience across product development, commercialization, technology, and company building. Together, they explain how Features Capital evaluates companies through both the future financial opportunity and the immediate execution path required to reach it.
Their investment approach begins with the team. Founder grit matters, but Jeff argues that conviction becomes far more valuable when it is paired with self-awareness, the ability to absorb feedback, and the discipline to make meaningful strategic adjustments before capital is wasted.
Clinical trials become another critical part of the conversation. Patient enrollment, site performance, study complexity, endpoint selection, and patient retention can materially change both development timelines and capital requirements, making clinical strategy an important component of venture strategy.
Jenny and Jeff also explain why fast followers can become compelling MedTech investments when earlier companies have already established portions of the regulatory and reimbursement roadmap. Strong differentiation combined with faster execution, better outcomes, and greater capital efficiency can create meaningful competitive advantages.
The conversation also explores AI-enabled biosensors, implantable medical devices, neurostimulation, cardiovascular innovation, metabolic health, precision medicine, minimally invasive therapies, and the continued importance of M&A as an exit pathway in MedTech.
For MedTech founders and investors, this episode provides a practical framework for thinking about the journey from early technical proof to clinical adoption, institutional capital, commercialization, and ultimately strategic value.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuria
#medtech #medtechindustry #venturecapital #medicaldevices #healthcareinnovation
Unlocking Capital for Medtech Through QSBS
2026/09/22
In this solo episode, Omar Khateeb takes a deeper look at Qualified Small Business Stock, Section 1202, and the potential impact of QSBS on MedTech venture economics.
The discussion begins with one of the industry’s most persistent challenges: MedTech requires significant capital and long development timelines before a company reaches regulatory approval, reimbursement, manufacturing scale, commercial adoption, or an eventual exit.
Omar explores whether QSBS could help improve the after-tax return profile of successful MedTech investments, potentially making the sector more attractive to venture investors and limited partners competing across multiple asset classes.
The episode explains why the 2025 changes matter, including partial exclusions beginning earlier in the holding period, a higher gross-assets threshold for qualifying companies, and a larger headline exclusion limit.
Omar also examines which MedTech business models may deserve closer review for QSBS treatment, particularly product-driven companies built around medical devices, implants, surgical robotics, diagnostic technologies, intellectual property, engineering, and clinical evidence.
For founders, the episode highlights several structural considerations, including domestic C corporation status, newly issued shares, secondary transactions, gross assets, and the timing of financing decisions.
For venture funds, the conversation moves into an even broader question: whether QSBS can become part of portfolio construction, underwriting, LP fundraising, and after-tax performance strategy.
Omar also introduces Section 1045, which may provide a pathway for certain qualifying investors to reinvest proceeds from an earlier exit into another eligible company, potentially helping capital move from one successful MedTech investment into the next.
The central thesis is that QSBS should be viewed as a potential capital formation mechanism rather than simply a tax strategy, because stronger after-tax outcomes can influence where investors choose to allocate capital.
This episode is educational only and does not constitute tax, legal, accounting, or investment advice.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training: https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston https://www.campcuriae.com/
#medtech #medtechindustry #venturecapital #startupfunding #founder
Venture Capital: Aneta Sottil of Andera Partners on Building MedTech Companies Investors Can Scale
2026/09/20
In this episode, Omar Khateeb joins Aneta Sottil, Partner at Andera Partners, for an in-depth conversation about MedTech investing, AI, category creation, commercialization, strategic M&A, and the signals that make healthcare innovation attractive to experienced venture investors.
Aneta explains how the MedTech investment standard has evolved. Early technical promise still matters, but investors increasingly want stronger human data, evidence of meaningful clinical benefit, economic viability, reimbursement clarity, commercial potential, and a credible pathway toward value creation and liquidity.
For companies building entirely new categories, Aneta focuses on whether the technology can move from being an interesting innovation to becoming something physicians and healthcare systems consider essential. The product needs to improve the patient care pathway in a way that is both clinically significant and economically sustainable.
The conversation also explores the relationship between AI and traditional MedTech. While patented devices, implants, delivery systems, and other physical technologies can offer strong defensibility, Aneta believes future winners will increasingly integrate AI into product development, analytics, data interpretation, and predictive capabilities.
Omar and Aneta discuss the evolving strategic buyer landscape, renewed MedTech M&A activity, surgical robotics, BCI, neuromodulation, reimbursement pathways, and the role experienced investors can play beyond providing capital.
Aneta shares examples involving microsurgical robotics, neuromodulation for asthma, wearable defibrillation, and BPH technologies, demonstrating how investment decisions connect clinical need with market structure, team quality, commercialization strategy, and patient impact.
The conversation ultimately highlights a broader principle for founders: creating MedTech value requires alignment between the product, clinical evidence, commercial strategy, investors, and the long-term direction of the company.
DISCLAIMER
This podcast is for informational and educational purposes only and is not financial, investment, legal, or medical advice. Views expressed are those of the hosts and guests and do not necessarily reflect State of MedTech LLC. Nothing discussed is a recommendation to buy, sell, or hold any investment or security. Conduct your own due diligence and consult qualified financial, legal, medical, or other professionals before making decisions.
Are you a MedTech CEO who needs marketing help to attract investors and grow your sales pipeline? Visit GrowMyMedtech.com to book a free analysis.
SUBSCRIBE
YouTube: https://www.youtube.com/@thestateofmedtech
LinkedIn Newsletter: https://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/
FOLLOW THE STATE OF MEDTECH
LinkedIn: https://www.linkedin.com/company/thestateofmedtech/
Instagram: https://www.instagram.com/stateofmedtech/
TikTok: https://www.tiktok.com/@stateofmedtechpod
X: https://x.com/stateofmedtech
Facebook: https://www.facebook.com/stateofmedtech
FOLLOW OMAR M. KHATEEB
LinkedIn: https://www.linkedin.com/in/okhateeb/
Instagram: https://www.instagram.com/omar.m.khateeb/
TikTok: https://www.tiktok.com/@omar.m.khateeb
X: https://x.com/OmarMKhateeb
Facebook: https://www.facebook.com/OmarMKhateeb
Watch Omar’s Market Engineering Training:
https://youtu.be/KSy8tZGMfCo?si=WGedZ_VJ1oCkITNf
Join Omar at Medtech CEO Camp in Boston:
https://www.campcuriae.com/
#medtech #medtechinnovation #venturecapital #medicaldevices #healthcareinnovation
Podcast reviews
Read State of Medtech podcast reviews
5 out of 5
172 reviews
★★★★★
nickd717 2026/10/27
Best medtech podcast
Omar is a great host and likes to go beyond the usual conventional material. If you want to see where medtech is headed, this is your show.
★★★★★
danaa8 2026/08/27
Well worth a listen
As someone interested in both medicine and technology, I really enjoy State of MedTech. Omar makes the business and science behind healthcare innovati...
★★★★★
miktremblant 2026/03/05
Thank you!
I’ve been absolutely loving your US Surgical podcast series. I love all your podcasts - but this series is really hitting home. It is great to hear st...
★★★★★
Jeradler23 2026/03/02
Worth the time
Omar provides tremendous value to his audience with every one of these podcasts. You will learn something worthwhile…. Guaranteed!
★★★★★
minec123 2025/12/26
Truly state of art podcast.
Omar captures the details and angles that get to the root of medtech.
★★★★★
DoubleDeePT 2025/12/05
Engaging Speaker
Omar Khateeb, host of the State of MedTech podcast, recently spoke to STRIPES, our women’s MedTech group about the complexities of posting content onl...
★★★★★
GS-work 2025/11/22
My go-to podcast for medtech
Really enjoy these podcasts. Thank you, Omar. Particularly like the ones with Nick from LSI.
★★★★★
Tjtrad 2025/10/02
Dr Albert episode
Loved all the questions and insights.
★★★★★
b022723 2025/04/03
Fresh perspectives and insightful healthcare conversations
Omar delivers an excellent podcast with relevant and diverse topics, and continually interesting guests. Each episode offers fresh perspectives with c...
★★★★★
hqnews 2025/01/17
Engaging
Omar is intensely curious and passionate which makes for a dynamic exchange and interesting and important lessons being shared.